Sanofi has reduced the price of Lantus (insulin glargine injection) 100 Units/mL by 78%, which is Sanofi's most widely prescribed insulin. Sanofi is capping the out-of-pocket costs at $35 for people with commercial insurance.
Sanofi announced that these effects will come into effect in January 2024. These measures are in addition to reducing unbranded Lantus by 60%. Sanofi further announced that it would reduce the price of Apidra by 70%.
Sanofi stated that
All patients with commercial insurance are eligible for Sanofi's copay assistance programs.
All patients with commercial insurance are eligible for Insulins Valyou Savings Program, where patients are eligible to pay only $35 for a 30-day supply.
Further, Sanofi stated that free insulins would be provided to low- and middle-income patients through the Sanofi Patient Connection program.
From the beginning of 2023, Sanofi insulins were included as a part of the Inflation Reduction Act, capping the maximum out-of-pocket cost of $35 per month for Senior Citizens.
Eli Lilly has announced significant price cuts for its insulin products, as well as capping out-of-pocket costs for patients. The company's insulin products will be available for up to 70% less than their current prices.
From May 1, 2023, Lilly will reduce the list price of non-branded insulin, Insulin Lispro Injection 100 units/mL, to $25 a vial.
From Q4 of 2023, Lilly announced that it would reduce Humalog (insulin lispro injection) 100units/ml and Humulin (insulin human) prices by 70%
Rezvoglar, a biosimilar of Lantus, will be available for $92 per five-pack of KwikPens.
Further, Lilly announced a cap on the out-of-pocket costs of $35 per month, immediately effective for people with a commercial plan. People who are not having insurance can also download the Lilly Insulin Value Program savings card and can get insulins at $35 per month.
The high cost of insulin has been a major issue for patients with diabetes, and Eli Lilly's attempt was to make insulin more accessible and affordable.
Furthermore, Eli Lilly announced that capping the amount for patients with commercial plans at $35 per month will make it easier to access their medication without facing financial hardship.
Novo Nordisk announced the results of Phase 3a ONWARDS trial, demonstrating the superiority of once-weekly insulin icodec in reducing HbA1C versus once-daily basal insulin in people with type-2 diabetes.
The ONWARDS is a Phase 3 52-week, open-label study in 1,085 insulin naive people with type 2 diabetes. Once weekly, insulin icodec was administered with the help of a dosing guide app for titration.
The ONWARDS trial met the primary endpoint of demonstrating non-inferiority in the reduction of HbA1c at 52 weeks compared to once-daily basal insulin. From the baseline of 8.9% in HbA1c, insulin icodec showed superiority in reducing the estimated HbA1c by -1.68% versus -1.31% in patients on once-daily basal insulin.
There was no statistically significant difference in hypoglycemia between the two insulins.
Novo Nordisk announced that it will approach regulatory agencies of the US, the EU, and China in the first half of 2023 for approval of once-weekly insulin icodec.
Comments